|
KLRC4-KLRK1
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression |
BEFREE |
Studies have shown that CD4CD25Foxp3Treg cells suppress NKG2D expression on NK cells via a cell contact-dependent mechanism and increased TGF-β and IL-10 production in some cancer models.
|
31145286 |
2019 |
|
KLRC4-KLRK1
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression |
BEFREE |
The present study provides evidence that activation of LXR, by enhancing NKG2D ligand expression, can promote NK cell-mediated cytotoxicity and suggests a novel immune-mediated mechanism involving modulation of intracellular cholesterol levels in cancer cells.-Bilotta, M. T., Abruzzese, M. P., Molfetta, R., Scarno, G., Fionda, C., Zingoni, A., Soriani, A., Garofalo, T., Petrucci, M. T., Ricciardi, M. R., Paolini, R., Santoni, A., Cippitelli, M. Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms.
|
31125275 |
2019 |
|
KLRC4-KLRK1
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
Here, we review the current knowledge on the impairment of NKG2D-mediated cancer immunity through TGF-β and discuss therapeutic approaches aiming at counteracting this major immune escape pathway.
|
31803194 |
2019 |
|
KLRC4-KLRK1
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
|
30778749 |
2019 |
|
KLRC4-KLRK1
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
In this review, we summarize the major findings regarding the antitumor immune response mediated by the NKG2D receptor and its ligands, and discuss the potential clinical applications of targeting the NKG2D/NKG2DL pathway for immunotherapy in cancer patients.
|
31720075 |
2019 |
|
KLRC4-KLRK1
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression |
BEFREE |
The immunomodulatory effects are consistent with a putative improvement in cancer immunosurveillance via the upregulation of the NKG2D receptor.
|
31234376 |
2019 |
|
KLRC4-KLRK1
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
Our findings demonstrated that NKG2D CAR-T cells targeted glioblastoma cells and cancer stem cells in an NKG2D-dependent manner, supporting the use of CAR-T therapy in glioblastoma therapeutic strategies.
|
31288857 |
2019 |
|
KLRC4-KLRK1
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
Based on a thorough understanding of the NKG2D/NKG2DL system as well as of the most relevant escape strategies of tumors, the diligent and thoughtful design of novel treatment modalities harnessing the NKG2D/NKG2DL axis holds great promise for the future therapy of cancer.
|
30732494 |
2019 |
|
KLRC4-KLRK1
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
Here, we review the post-transcriptional and post-translational mechanisms by which NKG2D ligands are modulated in cancer cells and their impact on patient prognosis.We discuss controversies and approaches to apply our understanding of the NKG2D ligand/NKG2D-axis for cancer therapy.
|
30254634 |
2018 |
|
KLRC4-KLRK1
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
Collectively, we demonstrated that the CS1-NKG2D biAb facilitated an enhanced immune synapse between CS1<sup>+</sup> MM cells and NKG2D<sup>+</sup> cytolytic innate and antigen-specific effector cells, which, in turn, activated these immune cells for improved clearance of MM.<i>Cancer </i>.
|
29769244 |
2018 |
|
KLRC4-KLRK1
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
Since the detection of ligands for NKG2D in sera of cancer patients is, in many human models, indicative of prognosis, a large number of studies have been undertaken to improve understanding of the biology regulating this receptor and its ligands, with the aim of translating this knowledge into clinical practice.
|
29521021 |
2018 |
|
KLRC4-KLRK1
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
Immune recognition through NKG2D is implicated in cancer, atherosclerosis, transplant rejection, and inflammatory diseases, such as rheumatoid arthritis.
|
29279329 |
2018 |
|
KLRC4-KLRK1
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
Our data provide a rationale to combine NKG2D-based immunotherapies with TMZ and IR.<i>Clin Cancer Res; 24(4); 882-95.©2017 AACR</i>.
|
29162646 |
2018 |
|
KLRC4-KLRK1
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
This event made the glioblastoma cells a potent target for NK cell-mediated recognition through a NKG2D restricted mechanism. p53 siRNA-mediated knock-down and pharmacological inhibition (pifithrin-α), profoundly prevented the iPA action in restoring the immunogenicity of U343MG cells through a mechanism that is dependent upon p53 status of malignancy.
|
28884474 |
2018 |
|
KLRC4-KLRK1
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
NKG2D ligands (NKG2DLs) are expressed on various tumor types and immunosuppressive cells within tumor microenvironments, providing suitable targets for cancer therapy.
|
29980239 |
2018 |
|
KLRC4-KLRK1
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
Harnessing NKG2D pathway is considered a viable avenue in cancer immunotherapy over recent years.
|
29525346 |
2018 |
|
KLRC4-KLRK1
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
With a focus on the liver, here, we review current knowledge of NKG2D-mediated tumor surveillance and discuss evidence supporting a dual role for NKG2D in cancer immunity.
|
30150983 |
2018 |
|
KLRC4-KLRK1
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
In this article, we review the recent developments of the fusion proteins with NKG2D/NKG2DL ligands in cancer immunotherapy.
|
29316666 |
2018 |
|
KLRC4-KLRK1
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
The specific examples of NKG2D and Erb-B are used that provide different characteristics and target profiles for CAR T-cell therapy of cancer.
|
28771104 |
2017 |
|
KLRC4-KLRK1
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
Previous studies raise the possibility that cancer cell NKG2D may induce high malignancy traits, but its full oncogenic impact is unknown.
|
28499126 |
2017 |
|
KLRC4-KLRK1
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
The elucidation of a CD8<sup>+</sup> T cell-dependent mechanism suggests that activated NKG2D<sup>+</sup>CD8<sup>+</sup> T-cell therapy alone may be able to restore the NKG2D ligand in tumors.<i>Cancer </i>.
|
28223282 |
2017 |
|
KLRC4-KLRK1
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
<b>Purpose:</b> NKG2D ligands (NKG2DL) are expressed on various tumor types and immunosuppressive cells within tumor microenvironments, providing suitable targets for cancer therapy.
|
28659311 |
2017 |
|
KLRC4-KLRK1
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
Our findings expose the need to selectively target the types of cancer that could benefit from NKG2D-based immunotherapy.
|
28128200 |
2017 |
|
KLRC4-KLRK1
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
The treatment of cancer through the induction of natural killer group 2, member D (NKG2D) ligands is of interest, but understanding of mechanisms controlling expression of individual ligand is limited.
|
28850101 |
2017 |
|
KLRC4-KLRK1
|
Primary malignant neoplasm
|
0.100 |
Biomarker |
BEFREE |
Research into the NKG2D mechanism of action has primarily been focused on cancer and viral infections where cytotoxicity evasion is a concern.
|
28926962 |
2017 |